A2 Milk halts trading amid potential acquisition
Kiwi dairy group A2 Milk (ASX:A2M) has moved its shares from a trading pause to a halt, with a "potential acquisition" in its sights.
Read MoreTag: A2M
A2 Milk shares plunge on weak outlook
A day after seeing its shares rise nicely on the peace pact with Synlait (ASX:SM1), its once key supplier, A2 Milk (ASX:A2M) saw its shares sold off heavily on Monday after reality hit in the form of a moderately OK 2023-24 results but weak outlook.
Read Morea2 Milk and Synlait end bitter feud
Kiwi dairy groups, a2 Milk (ASX:A2M) and Synlait (ASX:SM1), have kissed and made up after their recent split that nearly pushed Synlait to the wall.
Read MoreHigh-stakes dairy drama
A high-stakes game of dairy "Russian Roulette" is unfolding across the Tasman between struggling Synlait and its once-close buddy and customer (and shareholder), a2 Milk.
Read MoreAnalysis of a2 Milk and HUB24
Fund Manager Chris Pedersen discusses global markets, best and worst performers in January, the relation between consumer sentiment and recessions, debt to GDP, HUB24 and The a2 Milk Company.
Read MoreA2 Milk reports 27% profit increase in 2022-23 amid challenges in Chinese market
The A2 Milk Company (ASX:A2M) has announced a notable 27% rise in profit for the fiscal year 2022-23.
Read MoreSynlait Shares Soar on a2’s China Approval News
Synlait shares jumped nearly 15% Tuesday on news that Chinese regulators approved partner a2 Milk’s China label baby formula – a2 was up less than 2%.
Read MoreSynlait Hits Record Low as Outlook Spoils
A bad Wednesday for Kiwi dairy groups Synlait Milk and A2 Milk, with both under pressure from nervy investors and Synlait shares sold off 25% to a record low.
Read MoreBourse Discourse: BEN, ADH, A2M
The final week of this reporting season kicked off yesterday with results from, among others, regional bank Bendigo and Adelaide, retailer Adairs and Kiwi dairy leader A2 Milk.
Read MoreMarket Froths Up a2 Shares after FDA Formula Deal
a2 Milk has joined the list of companies who have won approval to supply baby formula to the US to fill a growing supply gap from a domestic shortage across the country.
Read MoreDefiant a2 Milk Finally Creams It
A Monday trifecta for the embattled a2 Milk company – beating 2021-22 profit estimates, promises of more to come, and a share buyback for its long-suffering shareholders.
Read MoreA2M – Credit Suisse rates the stock as Neutral
Neutral rating and $5.15 target price retained.
Read MoreAustralia’s Impact on the U.S. Infant Milk Powder Crisis
Peter Milios looks at whether Bubs Australia and a2Milk are merely a temporary fix to the current US baby formula shortage or set to disrupt an oligopoly within the US market?
Read MoreBubs Locks Down Mother of All Deals, A2 to Follow
Bubs Australia has struck a mega deal to send 1.25 million tins of baby formula to desperate parents in the US, and Monday saw A2 Milk join the rush and offer a deal of its own.
Read MoreA2M – Credit Suisse rates the stock as Neutral
The Neutral rating and target price of $5.75 are retained.
Read MoreMarket Morsels: ADH, SUL, SHL, A2M
Pandemic-related damage popped up in a couple of interims from retail groups on Monday, while Sonic Healthcare’s good run may just be petering out and A2 Milk’s luck about to turn.
Read MoreA2M – UBS rates the stock as Buy
The Buy rating and target price of NZ$10.20 are retained.
Read MoreA2 Left on the Doorstep in NZ Dairy Boom
Returns to the NZ dairy industry are close to record highs and yet shares in a2Milk slumped more than 12% at one stage on Wednesday as it became clear the company was being left behind in the boom.
Read MoreMuch Crying, Much Spilt Milk at a2
One-time glamour stock a2Milk confirmed on Thursday that it is one of the biggest corporate casualties of the Covid pandemic with a 77% slump in earnings for the year to June.
Read MoreA2M – Credit Suisse rates the stock as Underperform
UBS upgrades EPS forecasts for FY22 and FY23 by 2% and 4%, and raises the target price to $5.50 from $5. The Underperform rating is unchanged.
Read MoreA2M – Citi rates the stock as Sell
Sell and $5.85 target retained.
Read MoreWhen the Hype Disappears and Fundamentals Reappear
Anton Tagliaferro from Investors Mutual explains why stocks which can generate a lot of hype and capture the headlines for a time are no substitute for quality businesses trading at a reasonable price.
Read MoreA2M – UBS rates the stock as Buy
The Buy rating is maintained. The target is reduced to NZ$13.50 from NZ$15.50.
Read MoreA2 Sours Further, Incitec Soils Itself Again
Further downgrades from the once high-flying A2Milk and fertiliser maker Incitec Pivot on Monday – not the first for either company, both of which are turning into serial offenders.
Read MoreA2M – UBS rates the stock as Buy
UBS pins its Buy rating on a meaningful recovery in indirect infant formula sales over the next two years. Target is steady at NZ$16.00.
Read MoreA2M – UBS rates the stock as Buy
UBS believes tracking Australasian infant formula sales has become more challenging amid a disconnection from Australian exports. Buy rating and target of NZ$16.00.
Read MoreA2 Milk Curdles with Further Downgrade
Shares in A2 Milk crashed 20% at one stage yesterday after another downgrade was revealed and suggestions another could be in the offing, with no sign of an improvement in sales growth into China.
Read Morea2 Milk moves to complete Matura Valley Milk purchase
Struggling A2Milk has moved to complete the acquisition of a majority stake in rival Kiwi dairy group, Matura Valley Milk from a Chinese company that was first proposed in August. The purchase and subsequent investment in new plant will cost close to $A400 million.
Read MoreSales Slowdown Hits a2 Milk Guidance
As was widely feared, a sharp slowdown in sales to China has materialised for a2 Milk, which has significantly downgraded guidance for FY21.
Read MoreSouring A2 Milk Warns On “More Significant And Protracted” China Outlook
The first A2 Milk downgrade came in September, the day after the peak price was hit, and then at the AGM in November, management again downplayed the outlook for the year. Friday saw the downgrade crystalise when the company warned the impact had been “more significant and protracted than was previously anticipated”.
Read MoreA2M – UBS rates the stock as Buy
a2 Milk is in a trading halt ahead of a potential update to its guidance. UBS maintains its Buy rating with a target of NZ$20.50 / $A13.28.
Read MoreA2M – UBS rates the stock as Buy
a2 Milk has kept its guidance intact for revenue in the first-half to be $725-$77m along with an FY21 revenue of $1.80-$1.90bn.
Read MoreA2 Milk Confirms Guidance But Warns On “Short Term Softness”
The A2 Milk Company fell yesterday despite the company reaffirming earlier revenue guidance for the half-year to December and the June 30 full year.
Read MoreDaigou Drought Sours a2 Milk Outlook
Sales of a2 Milk’s infant formula within China remain robust but the slump in daigou sales has caught the market napping and forecasts for FY21 are downgraded sharply.
Read Morea2 Milk Outlook Sours On Daigou Disruption
Pop goes another ASX China consumer bubbler – Blackmore’s, Bellamy’s, and now a2 milk have all flown high on the China consumer (and the daigou or local buyer) boom.
Read MoreA2M – UBS rates the stock as Buy
a2 Milk has made an offer to acquire 75% interest in Mataura Valley Milk for $270m as part of its long-term strategy to participate in infant formula (IF) manufacturing.
Read MoreInvestors Pile Into Wisetech, Sour On A2 Milk
Two solid results from growth stocks yesterday – Wisetech and A2Milk – drew very different reactions from investors. Shares in Wisetech, the logistics software group with global ambitions soared by more than 37%, but for the a2 Milk, a bit of a thumbs down as the shares fell more than 6% in the wake of the release of the 2019-20 results.
Read MoreIs There More Upside For a2 Milk?
A2 Milk has been a beneficiary of the pandemic restrictions, with strong sales in online and re-seller channels, but will the effect of stockpiling subsequently unwind – and sharply?
Read More“Above Expectations”: Stockpiling Lifts A2 Milk
A2Milk has already emerged as a beneficiary of the COVID-19 pandemic and lockdowns in that the slide in sales missed it. Yesterday the company it more flesh on that suggestion with a further update of its performance so far this year and an upgrade to its guidance for the year to June.
Read MoreUpbeat a2 Lifts Profit Amid China Milk Boom
The a2Milk Company surprised yesterday with a solid result and update that made it clear the company is getting benefits from the COVID-19 crisis in China.
Read More
